the dark side of semaglutide and Ozempic-like drugs may improve kidney disease outcomes Ozempic and GLP-1 Drugs: Risk

15.87% ( N = 229,619) of inpatients had ASCVD, a majority of which featured coronary artery disease, 6.40% ( N = 92,539) of inpatients were classified as obese, with 3.00% assigned to obesity grade I, 1.68% to grade II, 1.45% to grade III, and 0.27% referred to unspecified levels of obesity

& Chesselet, M.-F

-Reduce stretch marks

GLP-1 agonists are a whole class of drugs with various generic and brand names semaglutide (Ozempic/Wegovy/Rybelsus), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Saxenda/Victoza) and tirzepatide (Mounjaro/Zepbound) to name a few

No matter your method, its important to be vigilant about how prescription medications affect your well-being